Company news
Xenon Pharmaceuticals Inc. news in 2020
Xenon Pharmaceuticals Inc.'s news releases, calls and decks from 2020, newest first.
Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at AES2020, the Virtual Annual Meeting of the American Epilepsy Society
December 6, 2020
Xenon Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 4, 2020
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2020 Financial Results and Provide Corporate Update
November 1, 2020
Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE Before Year-End
October 7, 2020
Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy
October 7, 2020
Xenon Pharmaceuticals Appoints Dr. Chris Von Seggern as Chief Commercial Officer
August 16, 2020
Xenon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 5, 2020
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update
July 29, 2020
Xenon Pharmaceuticals to Present at the Jefferies 2020 Virtual Healthcare Conference
May 31, 2020
Xenon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 20, 2020
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Provide Corporate Update
May 13, 2020
Xenon Pharmaceuticals Provides Corporate Update in the Context of COVID-19
March 30, 2020
Xenon Pharmaceuticals Reports 2019 Financial Results and Provides Corporate Update
March 8, 2020
Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss 2019 Financial Results and Provide Corporate Update
March 1, 2020
Xenon Pharmaceuticals Announces Full Exercise and Closing of Underwriters’ Option to Purchase Additional Shares
February 13, 2020
Xenon Pharmaceuticals Announces Closing of its $60.0 Million Public Offering of Common Shares
January 26, 2020
Xenon Pharmaceuticals Announces Pricing of $60.0 Million Public Offering of Common Shares
January 21, 2020
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update
January 12, 2020